ArticleScientific reports2025
Crotonoside exerts anti-colorectal cancer effects by suppressing KIF20A to regulate the cell cycle.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- LC-MS/MS Determination of Crotonoside in Rat Plasma and Application to Pharmacokinetic Study.Biomedical chromatography : BMC · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Crotonoside (CTS) is a primary bioactive component found in Croton. current research has mainly focused on leukemia, with few reports in other cancers. Considering the traditional use of Croton, this study aims to evaluate the anti-colorectal cancer (CRC) activity of CTS and reveal its potential mechanisms. First, results in vitro show that CTS can markedly suppress CRC cell proliferation, invasion and migration, and EMT pathway (P < 0.01). Then, RNA-seq analysis was employed to identify the core target and potential mechanism of CTS against CRC, and the results suggested KIF20A is a core target. Bioinformatic analysis showed that KIF20A is overexpressed in CRC and associated with a worse prognosis (P < 0.01). KEGG and GO enrichment analyses indicated that anti-CRC activity of CTS is linked to the cell cycle. Next, Results confirmed that CTS can promote the expression of CDK1 and Cyclin B1 (P < 0.01), and induces G2/M phase arrest to exert anti-CRC effects (P < 0.01). Then, a subcutaneous tumor model was established in vivo to evaluate the anti-CRC activity of CTS; the results showed that CTS significantly inhibited CRC tumor growth and reduced both tumor weight and volume (P < 0.01). CTS can suppress the expression of Ki67, E-cadherin, vimentin, and KIF20A (P < 0.05), and promote the expression of Cyclin B1 and CDK1 (P < 0.01). In addition, molecular docking analysis revealed that the binding energy of CTS to KIF20A was - 7.9 kcal/mol, and CETSA assay showed that CTS treatment attenuated the thermal degradation of KIF20A protein. These results showed CTS can bind KIF20A tightly. Finally, overexpression of KIF20A reverses the anti-CRC effect of CTS. In summary, this study confirms that CTS can target and inhibit KIF20A, thereby inducing cell G2/M phase arrest and exerting anti-CRC effects.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.